&w=3840&q=100)
Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra
Around 1:05 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 1.82 per cent at ₹1,712.50 per share. In comparison, BSE Sensex was trading 0.71 per cent higher at 82,636.70 levels.
Why did Glenmark Pharmaceuticals share price rise today?
Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation (CDSCO).
Tevimbra is a uniquely engineered anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology innovator focused on delivering cutting-edge cancer therapies.
The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC).
The launch marks Glenmark Pharmaceuticals' entry into the immuno-oncology space in India and is a key step in broadening its oncology portfolio with innovative therapies.
NSCLC accounts for over 80 per cent of all lung cancer cases, while ESCC is the most prevalent histological subtype of esophageal cancer in India. Tevimbra addresses the major treatment needs of this large patient base with a differentiated and evidence-backed option, the company said.
Already approved and available in major markets including the US, EU, Australia, and China, Tevimbra is designed to selectively bind to PD-1 receptors, restoring T-cell function and limiting off-target immune suppression. It has shown strong efficacy and a favourable safety profile across various solid tumors in multiple Phase 3 studies and a global clinical programme.
Glenamark Pharmaceuticals Q4 results
For the fourth quarter of FY2024-25 (Q4FY25), Glenmark Pharmaceuticals reported a consolidated revenue of ₹3,256.2 crore, marking a year-on-year (Y-o-Y) growth of 6.3 per cent from ₹3,063 crore in the same period last year. The company's Ebitda for the quarter stood at ₹560.7 crore, up 11.2 per cent from ₹504.3 crore, with an Ebitda margin of 17.2 per cent. Adjusted Profit After Tax (PAT) for the quarter came in at ₹346.6 crore, reflecting an adjusted PAT margin of 10.6 per cent.
For the full fiscal year ended March 31, 2025 (FY25), the company's consolidated revenue rose 12.8 per cent to ₹13,321.7 crore, compared to ₹11,813.1 crore in the previous year. Ebitda for FY25 more than doubled to ₹2,351 crore from ₹1,195.3 crore, with the Ebitda margin improving to 17.6 per cent. The company also posted an adjusted PAT of ₹1,389.4 crore for the year, resulting in an adjusted PAT margin of 10.4 per cent.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology, and oncology.
With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, Glenmark Pharmaceuticals has established itself as a major player in the global pharmaceutical landscape.
The market capitalisation of Glenmark Pharmaceuticals is ₹48,171.68 crore, according to BSE. The company falls under the BSE 500 index.
Glenmark Pharmaceuticals' 52-week high is ₹1,830.05 per share, while its 52-week low is ₹1,199.95 apiece.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
7 hours ago
- The Print
Stock markets muscle through intense volatility amid buying rush in heavyweights
The 50-share NSE Nifty inched up by 55.70 points or 0.22 per cent to 25,461. After oscillating between highs and lows in intra-day trade, the 30-share BSE Sensex ended 193.42 points or 0.23 per cent higher at 83,432.89. During the day, it hit a high of 83,477.86 and a low of 83,015.83, gyrating 462.03 points. Mumbai, Jul 4 (PTI) Benchmark indices Sensex and Nifty ended higher on Friday in a highly volatile trade amid a buying rush in banking and other bellwether stocks on the back of a rally in the US markets. From the Sensex firms, Bajaj Finance, Infosys, Hindustan Unilever, ICICI Bank, HCL Tech, UltraTech Cement, Bajaj Finserv, State Bank of India, Tata Consultancy Services, Reliance Industries, Axis Bank and Larsen & Toubro were among the major gainers. However, Trent, Tata Steel, Tech Mahindra and Maruti were among the laggards. 'The tone was negative in the first half; however, a decent recovery in heavyweight stocks pared all the losses as the day progressed, helping the index close near the day's high at the 25,461 level. 'With all eyes on the impending US-India trade deal as the tariff deadline approaches, participants are hopeful for a favourable outcome, which could provide the much-needed trigger for the next leg of the market up move,' Ajit Mishra – SVP, Research, Religare Broking Ltd, said. The BSE midcap gauge went up by 0.23 per cent and smallcap index climbed marginally by 0.17 per cent. Among BSE sectoral indices, oil & gas jumped 1.26 per cent, energy (0.90 per cent), realty (0.87 per cent), IT (0.67 per cent), healthcare (0.64 per cent), BSE Focused IT (0.65 per cent) and teck (0.52 per cent). Metal, telecommunication, auto, consumer discretionary and commodities were the laggards. As many as 2,261 stocks advanced while 1,788 declined and 140 remained unchanged on the BSE. 'The Indian market is experiencing a pause as investors adopt a wait-and-watch strategy ahead of the impending US tariff deadline with mixed global cues. Ongoing FII outflows reflect a risk-off approach, while DII inflows are offering partial support. 'Following the recent rally, main indices are hovering near peak valuation levels, limiting further upside, which is highly dependent on Q1 earnings and details of the trade deal,' Vinod Nair, Head of Research, Geojit Investments Limited, said. In Asian markets, Japan's Nikkei 225 index and Shanghai's SSE Composite index settled higher while South Korea's Kospi and Hong Kong's Hang Seng ended lower. European markets were trading in the negative territory. The US markets ended in the positive territory on Thursday. Global oil benchmark Brent crude dropped 1.03 per cent to USD 68.03 a barrel. Meanwhile, markets regulator Sebi has barred US-based Jane Street Group from the securities markets and directed the group to disgorge unlawful gains of Rs 4,843 crore for allegedly manipulating stock indices through positions taken in derivatives segment. This could be the highest disgorgement amount ever directed by the Securities and Exchange Board of India (Sebi). Foreign Institutional Investors (FIIs) offloaded equities worth Rs 1,481.19 crore on Thursday, according to exchange data. Domestic Institutional Investors (DIIs) bought stocks worth Rs 1,333.06 crore. On Thursday, the Sensex dropped by 170.22 points or 0.20 per cent to settle at 83,239.47. The Nifty declined by 48.10 points or 0.19 per cent to 25,405.30. 'Indian equity markets opened on a flat note Friday as investors remained cautious ahead of a potential India–US trade agreement and digested regulatory action against a major global trading entity. Both indices dipped during mid-session but recovered to end on a positive note…,' Gaurav Garg, Analyst, Lemonn Markets Desk, said. On the weekly front, the BSE benchmark gauge dropped 626.01 points or 0.74 per cent, and the Nifty declined 176.8 points or 0.68 per cent. PTI SUM HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
8 hours ago
- Time of India
Top American cardiologist shares 5 easy steps to lose 13 kg weight naturally, without any injection shot
The Five-Point Plan for Natural Weight Loss About Dr. Sanjay Bhojraj As weight-loss medications like Ozempic and Wegovy gain mainstream popularity, concerns about long-term side effects and dependency have also come into focus. In response, one of America's leading cardiologists has outlined a natural, evidence-backed alternative to help individuals lose up to 13.6 kilograms (30 pounds) without relying on injections or synthetic appetite suppressants. Dr. Sanjay Bhojraj, an interventional cardiologist and certified functional medicine practitioner, recently shared his step-by-step method for activating the body's own mechanisms to manage weight and improve overall doctor explained that injectable drugs such as Ozempic work by mimicking GLP-1, a hormone that helps regulate hunger and satiety. However, through strategic changes in diet and lifestyle, the body can be trained to increase its own production of GLP-1 naturally. In an post on Instagram, he outlined key habits that he has used in his functional medicine clinic to help patients lose significant weight while improving their energy, sleep, and mood—without the potential downsides of Bhojraj's approach is rooted in practical, sustainable adjustments rather than restrictive dieting. These five habits form the foundation of his method:Dietary fiber plays a crucial role in promoting satiety and stabilizing blood sugar levels. According to Dr. Bhojraj, fiber is a key nutrient for stimulating GLP-1 naturally, making it a non-negotiable part of every like olive oil and avocado oil not only support hormone balance but also help regulate appetite. These fats work by signaling the body to relax and increase fat metabolism , contributing to sustained energy levels and reduced order in which food is consumed affects how the body processes it. Eating protein first can help flatten the post-meal blood sugar spike and increase feelings of fullness, making it easier to eat less levels are influenced by the body's circadian rhythm. Bhojraj noted that consuming food earlier in the day—especially before 9 a.m.—leads to a higher natural release of GLP-1 compared to eating later in the eating, which involves chewing slowly and being present during meals, has been linked to better GLP-1 activity. In contrast, frequent snacking disrupts digestive rest and hormone regulation, which can impair natural appetite Bhojraj is a board-certified interventional cardiologist and a certified practitioner with The Institute for Functional Medicine. He is also the founder of Well12, a 12-week wellness program focused on evidence-based lifestyle interventions. His clinical approach covers areas such as genomic medicine, lipid testing, and epigenetics.
Business Standard
11 hours ago
- Business Standard
INR gains further ground at around 1-month high
The Indian rupee appreciated 16 paise to close at an over one-month high of 85.39 (provisional) against the US dollar on Friday, tracking a decline in the American currency in the overseas market and a weak tone in crude oil prices. Besides, rupee alongside other Asian currencies, gained ground on renewed hopes of trade deals with the US. US President Donald Trump announced a trade agreement with Vietnam, and that injected a dose of optimism that perhaps more such agreements could be in the pipeline before the crucial July 9 deadline. Meanwhile, the benchmark 30-share BSE Sensex ended the session up 193.42 points, or 0.23 percent, at 83,432.89, after having hit a low of 83,015.83 during intraday trade. The broader NSE Nifty index fell to 25,331.65 before reversing course to close up 55.70 points, or 0.22 percent, at 25,461 on optimism about India's upcoming trade deal with the United States.
